Annual Meeting of the NCI Cohort Consortium (Abstract Submission): Submission #12

Lightning Talks Abstract
------------------------






Presenter's First Name: : Benjamin









Presenter's Last Name:: Cairns









Title (eg: professor, assistant professor, chair, etc):: Dr









Degree(s): Ph.D.









Contact Email:: Ben.Cairns@ourfuturehealth.org.uk









Organization:: Our Future Health









Project Title:: Our Future Health: A New Prospective Cohort for Translational Research









Additional Authors:
1. First Name: Michael
   Middle Initial: B
   Last Name: Cook
   Degree(s): Ph.D.
   Organization: Our Future Health
2. First Name: David
   Middle Initial: J
   Last Name: Hunter
   Degree(s): M.B.B.S. MPH Sc.D.
   Organization: University of Oxford; Our Future Health
3. First Name: Raghib
   Last Name: Ali
   Degree(s): M.D. MPH
   Organization: Our Future Health










Abstract::
Background: Our Future Health is a new UK-wide prospective cohort study supported by the UK Government, industry and charity sectors. Our objective is to recruit 5 million adult residents of the UK to facilitate aetiologic and translational health research, aiming to discover and test more effective approaches to prevention, earlier detection and treatment of diseases. 

Methods: The sampling frame for Our Future Health is the total UK adult population. Through invitations and open enrolment, we aim to recruit a cohort that reflects the diversity of the UK population in terms of age, ethnicity, socioeconomic status and geography. Participants complete a questionnaire and attend an appointment for physical measurements and blood sampling, and are genotyped using a custom array with a genome-wide backbone for imputation and extensive coverage of disease- and phenotype-associated variants. Priority data linkages include primary and secondary care records, and cancer and death registrations, in each of the four UK nations.

Results: To date, 1.8 million participants have consented to join Our Future Health, of which 1.3 million have completed the broad baseline questionnaire and over 1 million have donated blood for genotyping and biobanking of plasma, buffy coat and DNA.

Discussion: Key translational aspects of the study include the forthcoming ability for study proposals to request access to baseline blood samples, and for investigator-led recontact studies to recruit participants based on demographics, phenotypes, genotypes or disease risk for risk-stratified research. Our Future Health (ourfuturehealth.org.uk) is already open for data access study proposals.